Medical Licensing (MD/DO) · Independent exam preparation
MDS Subspecialty Certification: Clinical Decisions and Practice Guide Study Guide
Study Mohs margin assessment, reconstruction, perioperative care, skin cancer staging, oncology treatments, and practice standards through 60 concepts and 20 explained questions.
By CertMedbry · Updated 15 October 2026
Connect microscopic findings with surgical anatomy, select repairs that preserve function, recognize perioperative emergencies, and distinguish margin clearance from cancer staging. These 60 selective concepts address all eleven listed domains. Use the official ABD outline as the full scope reference: its detailed topics extend beyond this guide, and ABD cautions that even its outline may not include every tested subject.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and qualification pathway does this guide address?
It addresses the ABD Micrographic Dermatologic Surgery (MDS) Subspecialty Certification Examination. Beginning with the 2026 administration, ABD requires completion of an ACGME-accredited Micrographic Surgery and Dermatologic Oncology (MSDO) fellowship. MSDO names the fellowship programme. This credential is physician subspecialty certification rather than initial medical licensure.
ABD: MDS Practice Pathway Ends in 2025 · ABD MDS Subspecialty Certification Examination Study Guide
What happened to the practice pathway?
The practice pathway ended with the 2025 administration. It previously allowed qualifying dermatologists who independently performed Mohs surgery after residency to apply without completing an MSDO fellowship. Those historical instructions do not establish eligibility for the 2026 administration.
Which outline version supports this guide?
The ABD preparation page links the five-page 2024-abd-mds-study-guide.pdf. The document internally states 'Last Updated: May 2, 2019.' Its filename does not establish a 2024 revision, and no separate effective date is stated. Treatment approvals and coding rules have their own dated references.
ABD MDS Exam Study Guide page · ABD MDS Subspecialty Certification Examination Study Guide
How many examination items are there?
ABD states that the examination contains 200 multiple-choice items. Its examination-format FAQ does not identify a scored/pretest split, so this is the stated total rather than a verified scored-item count.
What does the MDS subspecialty certification exam consist of?
What are the examination duration and delivery setting?
ABD describes an examination approximately four hours long, administered at Pearson VUE test centers. The cited examination-format FAQ does not establish whether testing is adaptive.
What does the MDS subspecialty certification exam consist of?
Which item style is verified, and what do these exercises reproduce?
ABD identifies multiple-choice items, and its outline includes slide-interpretation competence. The cited materials do not establish a current virtual-slide count or interface specification. These twenty original questions use four-option, single-best-answer exercises. Text exercises support clinical reasoning but cannot demonstrate actual slide interpretation or procedural competence.
What does the MDS subspecialty certification exam consist of? · ABD MDS Subspecialty Certification Examination Study Guide
Are official domain percentages or passing standards stated?
The linked outline publishes no numerical domain weights, and the cited preparation materials do not establish a passing score. This guide samples every listed domain. Its allocation of concepts and questions is educational rather than an official weighted examination model.
Which jurisdictions apply to the regulatory and medication examples?
CMS examples concern U.S. Medicare coding and laboratory certification; OSHA examples concern U.S. occupational requirements; FDA examples identify U.S. approvals. The British Society for Dermatological Surgery reference supports individualized bleeding-versus-thrombosis assessment. Its medication schedules are not presented as universal U.S. rules.
CMS Medicare NCCI Policy Manual 2026, Chapter III · Apply for a CLIA Certificate | CMS · OSHA 29 CFR 1910.1030—Bloodborne pathogens · BSDS Guidance on Antithrombotics and Skin Surgery 2023, Version 2023.6
These independently authored educational materials support preparation for the American Board of Dermatology's Micrographic Dermatologic Surgery subspecialty certification examination. The ABD outline establishes examination scope; the cited clinical and regulatory references support individual teaching points.
Outline used: Current ABD-linked study guide verified on 2026-10-09: filename 2024-abd-mds-study-guide.pdf; internal last-update date May 2, 2019. No separate effective date or numerical weights stated. The workbook label maps to this MDS certification examination; MSDO denotes the fellowship training programme.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Mohs specimen acquisition and processingnot stated
1.How does specimen orientation make a positive margin actionable?
Orientation preserves the relationship between excised tissue and the patient's wound. Surgical reference marks, corresponding map labels, and tissue inks must remain concordant through division, embedding, sectioning, and interpretation. A positive microscopic focus becomes actionable when it can be assigned to the correct peripheral sector or deep plane. Accurate localization permits another stage to address residual disease while conserving uninvolved tissue.
Apply it
A nasal specimen has two orientation marks, but the processing sketch reverses them. Reconcile the operative map, tissue markings, and processing record before directing another excision.
Common pitfall: Recognizing carcinoma does not compensate for a reversed map. Guessing its location can remove healthy tissue while leaving the involved wound sector untreated.
ACMS: The Mohs Step-by-Step Process · ABD MDS Subspecialty Certification Examination Study Guide
2.Why must the peripheral edge and deep surface be examinable together?
Mohs processing aims to display the peripheral and deep surgical margins in en face sections. Beveled acquisition or appropriate releasing techniques allow the peripheral edge to flatten with the undersurface during embedding. This geometry supports examination of the mapped surgical boundary. An edge that remains curled or incompletely represented is an unexamined region, even when the rest of the section contains abundant tumor-free tissue.
Apply it
A first-stage specimen displays a broad deep surface, but one epidermal edge remains upright in the block. Correct the embedding and obtain sections representing that peripheral margin.
Common pitfall: The amount of visible tissue does not establish completeness. Adequacy depends on whether the actual surgical boundary is present and interpretable.
ACMS Mohs Surgery Process infographic · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
3.How should additional stages conserve uninvolved tissue?
Additional stages follow mapped residual disease. An involved peripheral sector calls for directed peripheral removal; isolated deep involvement calls for appropriately directed deeper tissue. The ABD outline emphasizes narrow peripheral additions and shallow deep additions when suitable. Conservation depends on reliable localization and adequate examination. The next specimen must preserve orientation and demonstrate the new surgical boundary corresponding to the positive region.
Apply it
Only the central deep margin of a cheek defect contains tumor, while all peripheral sectors are adequately negative. Plan a mapped deep addition rather than automatically enlarging the entire circumference.
Common pitfall: Repeating a complete circumferential stage can sacrifice uninvolved tissue. Conversely, excessively limited sampling is inappropriate when orientation or margin adequacy is uncertain.
ABD MDS Subspecialty Certification Examination Study Guide · ACMS: The Mohs Step-by-Step Process
4.How does three-dimensional anatomy change Mohs mapping?
A flat map must preserve three-dimensional surgical relationships. Tissue involving an ear fold, muscle, cartilage, or a separately submitted deep component may contain surfaces that a simple clock face cannot adequately describe. Label each piece and plane so its relationship to the patient remains explicit. Before acting on a positive focus, determine which surface it represents and what anatomic structures lie beyond that surface.
Apply it
An auricular stage includes skin over cartilage and a separate deep component. Record their relationships individually so deep involvement cannot be mistaken for a positive external skin edge.
Common pitfall: Physical flattening does not simplify the underlying anatomy. A clock-face label without plane information may conceal whether the involved boundary is peripheral or deep.
ABD MDS Subspecialty Certification Examination Study Guide · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
5.How should a processing defect guide technical correction?
Useful frozen sections require preserved architecture, readable cellular detail, and representation of the intended margin. Determine whether the limiting defect concerns orientation, embedding, sectioning, or staining before choosing a remedy. A recut may resolve a fold or section defect; tissue standing outside the section plane may require re-embedding. Poor staining requires correction of the preparation rather than an unsupported diagnostic assumption.
Apply it
The expected tissue outline is present, but uneven staining prevents assessment of nuclei along one margin. Obtain a satisfactory preparation before interpreting that region as positive or negative.
Common pitfall: Repeated deeper sections can consume tissue without correcting the real problem. Select the technical intervention that addresses the observed obstacle to margin assessment.
ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1 · ABD MDS Subspecialty Certification Examination Study Guide
6.When should Mohs surgery stop before margins are clear?
Clearance does not override patient safety or anatomic limits. The ABD outline identifies extension into structures such as the orbit, ear canal, sinuses, urethra, anal canal, or bone as potential reasons to terminate Mohs without clear margins. Inadequate local anesthesia and excessive bleeding are additional considerations. Recognize when further resection exceeds the available setting, preserve an accurate account of residual disease, and coordinate continued treatment.
Apply it
Residual periocular carcinoma extends toward orbital structures, and further removal cannot be performed safely with available anesthesia. Stop, document the involved location, and arrange appropriate specialist management.
Common pitfall: A positive stage does not automatically justify another office-based stage. The depth of extension, available anesthesia, and patient's condition can change the appropriate treatment setting.
Mohs slide interpretationnot stated
7.How can nodular BCC be distinguished from a benign hair follicle on Mohs sections, and what can Ber-EP4 establish?
Nodular BCC forms aggregates of crowded basaloid cells, often with peripheral palisading and clefting between tumor and surrounding stroma. Central cells may appear disorganized. A tangentially sectioned benign follicle can also resemble a basaloid nest, but additional sections may reveal organized root sheaths and hair-shaft keratin. Palisading alone is insufficient because follicular structures can share that appearance, and BCC may lack conspicuous palisading. These discriminating features are illustrated in the [ACMS morphology teaching example](https://www.mohscollege.org/for-physicians/education/question-of-the-week/september-30-2020).
Apply it
When inflammation obscures suspected residual BCC, Ber-EP4 immunohistochemistry can highlight otherwise inconspicuous epithelial tumor aggregates. An [original Mohs study](https://pubmed.ncbi.nlm.nih.gov/9391566/) demonstrated this application. Interpret staining alongside architecture and corresponding H&E sections: a positive aggregate with crowded, disorganized basaloid cells and stromal clefting supports BCC more strongly than an organized follicular profile.
Common pitfall: Ber-EP4 positivity does not independently prove malignancy. Normal follicular and sweat-gland structures, including additional adnexal structures on frozen sections, can stain, as documented in an [original immunoreactivity study](https://pubmed.ncbi.nlm.nih.gov/8552575/). Written recognition cues do not demonstrate competence interpreting complete slides; supervised slide assessment remains necessary. This selective 60-concept guide samples the official ABD outline, the full scope reference, which ABD itself cautions is not exhaustive.
ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1 · ABD MDS Subspecialty Certification Examination Study Guide
8.How should artifacts influence a margin decision?
Artifacts may distort architecture, obscure cellular detail, or produce apparent abnormalities. Their significance depends on whether they affect a required margin and whether additional preparation can resolve the uncertainty. Assess the mapped location and surrounding tissue relationships before classifying a distorted focus. ACGME identifies artifact recognition, selection of recuts, and technical troubleshooting as specific Mohs histopathology competencies because each affects the reliability of interpretation.
Apply it
A folded peripheral edge creates a dark, crowded focus. Obtain a section with the fold resolved and reassess its architecture before diagnosing residual carcinoma or accepting the edge as negative.
Common pitfall: Calling every difficult focus tumor causes unnecessary removal; dismissing every difficult focus as artifact risks missed disease. Resolve the technical limitation before deciding.
ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
9.How should a microscopic finding be assigned to a tissue plane?
A positive slide must be interpreted in relation to the specimen's mapped surfaces. Determine whether the involved tissue represents a peripheral edge, a deep boundary, or a separately submitted component. This distinction determines the direction of additional removal. The same diagnosis can require different surgical action depending on its plane of involvement. Histologic recognition and anatomic localization therefore form complementary parts of the margin decision.
Apply it
Tumor is present in a separately labeled deep piece from an auricular defect, while external skin edges are adequately negative. Direct further evaluation toward that deep anatomic relationship rather than enlarging every skin edge.
Common pitfall: The location of a focus on the glass slide does not independently establish its location in the patient. Interpret it through the orientation and mapping record.
ABD MDS Subspecialty Certification Examination Study Guide · ACMS: The Mohs Step-by-Step Process
10.When do recuts and special stains answer different questions?
A recut provides another section through the embedded tissue and can clarify architecture or resolve a sectioning defect. A special stain addresses a selected diagnostic question about tissue already represented. Neither automatically repairs an absent surgical margin or a broken orientation chain. State the uncertainty first: missing boundary, unreadable morphology, or uncertain cellular identity. Then select preparation that can actually resolve that uncertainty.
Apply it
A folded section obscures a peripheral focus. Obtain an interpretable recut before deciding whether a targeted stain would add diagnostic information. If the edge itself was never embedded into the section plane, correct that geometry first.
Common pitfall: Additional staining cannot establish clearance of tissue that is absent. More laboratory work is useful only when it addresses the specific limitation.
ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1 · ABD MDS Subspecialty Certification Examination Study Guide
11.Why can the central debulking specimen change melanoma staging?
Peripheral and deep margin sections assess surgical boundaries; they do not necessarily characterize the deepest portion of the original central lesion. Vertical examination of a central debulking specimen can reveal invasive melanoma absent from the initial biopsy. The cited observational study demonstrates this staging utility in lentigo maligna and melanoma in situ. Newly identified invasion requires reassessment of the primary tumor even when mapped margins are negative.
Apply it
A lesion diagnosed as lentigo maligna has negative margins, but vertical central sections reveal dermal invasion. Incorporate the invasive findings into staging and reconsider management and regional staging discussions as appropriate.
Common pitfall: Clear margins and an in situ diagnosis answer different questions. Negative boundary sections cannot exclude invasion that was present within the removed central tumor.
Surgical defect repairnot stated
12.Which defect features should determine reconstruction?
Assess the final cleared defect's size, depth, location, adjacent tissue, and functional relationships before selecting reconstruction. Natural healing, direct closure, flaps, and grafts solve different problems. A small defect may be complex if closure displaces an eyelid or nasal margin, while a larger defect may close readily where tissue is mobile. The reconstructive plan must respond to the actual defect and patient's circumstances.
Apply it
A planned nasal linear closure becomes problematic when the final defect approaches the alar rim. Reassess tissue movement and expected distortion before committing to closure or selecting another method.
Common pitfall: Tumor diameter does not describe the final reconstructive problem. Subclinical extension, wound depth, and proximity to free margins can change the appropriate repair.
ACMS: Reconstruction · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
13.Which periocular defect characteristics favor second-intention healing over closure, grafting, or a flap?
Second-intention healing combines granulation, epithelialization, and wound contraction. Small, shallow defects in the medial canthal concavity can heal favorably because a slightly depressed scar may fit the existing hollow. Selection depends on depth, the vascular wound bed, and whether contraction could displace an eyelid margin or punctum. Concavity alone does not establish suitability; deeper wounds and defects extending toward a mobile margin require particular attention to traction.
Apply it
Consider a 6-mm shallow defect confined to the upper medial canthal hollow, with viable superficial orbicularis exposed, no bare bone or cartilage, intact canaliculi and canthal tendon, and no extension onto either eyelid margin. With normal lid position and reliable wound care, second intention is reasonable. Primary closure could distort the hollow if approximation creates traction. A full-thickness graft adds donor-site care and graft-take requirements; a glabellar flap may introduce unnecessary bulk and flatten the concavity.
Common pitfall: Do not extrapolate this choice to a larger, deeper lower-eyelid defect immediately beneath the free margin. Contraction there can shorten the anterior lamella and cause retraction or ectropion. Grafting or a suitably supported flap may better preserve tissue length, although grafts also contract. Follow lid position during healing rather than promising that nearby structures will remain undisturbed.
ACMS: Reconstruction · ABD MDS Subspecialty Certification Examination Study Guide · Eyelid Reconstruction - EyeWiki
14.How can closure forces threaten nearby free margins?
Direct closure transmits force into surrounding tissue as wound edges move together. Near an eyelid, lip, or nasal rim, the direction of that force may determine function. Assess tissue mobility, the proposed closure line, and displacement of nearby structures during trial approximation. A technically achievable closure can remain unsuitable when its tension predictably changes a free margin's position or compromises function.
Apply it
Gentle approximation of a lower-eyelid defect pulls the lid away from the globe. Use that observed displacement to redesign the repair before placing definitive sutures.
Common pitfall: Edges meeting does not establish an acceptable result. Tighter superficial sutures along the same unfavorable vector do not correct the underlying traction.
ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1 · ABD MDS Subspecialty Certification Examination Study Guide
15.What distinguishes a flap from a free skin graft?
A flap transfers tissue while retaining a vascular connection. A free skin graft is detached and initially depends on its recipient bed for nourishment and subsequent vascular integration. This distinction determines important planning and postoperative priorities. A flap requires preservation of its vascular connection during movement; a graft requires stable, broad contact with a suitable recipient surface. Donor-site proximity alone does not determine the category.
Apply it
Adjacent skin moved with its vascular attachment intact is a flap. Detached skin secured onto a wound is a graft, even when harvested from nearby skin.
Common pitfall: Calling every transferred skin segment a graft obscures its physiology. The retained vascular connection determines the distinction and helps explain different failure mechanisms.
ACMS: Reconstruction · University of Iowa: Split Thickness Skin Graft
16.How do advancement, rotation, and transposition flaps differ?
These categories describe tissue movement into a defect. Advancement primarily moves tissue forward, rotation swings tissue around a pivot, and transposition redirects tissue across adjacent tissue into the target. The movement helps identify the donor source, expected force directions, and vascular relationships. Apply the classification to an actual design rather than assuming that a familiar flap name establishes suitability for every defect.
Apply it
A curved cheek flap swings around a pivot into a defect. Recognize rotational movement, then assess the available laxity and the effects on nearby eyelid and lip positions.
Common pitfall: The same flap category can produce different tension and distortion depending on geometry and location. Naming the movement is the beginning of design assessment, not its completion.
ABD MDS Subspecialty Certification Examination Study Guide · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
17.Why does an interpolation flap with an exposed bridging pedicle require staged planning?
In a staged interpolation flap, tissue reaches a nonadjacent defect while an exposed pedicle bridges intervening intact tissue and initially maintains its vascular connection to the donor site. After the transferred tissue develops sufficient recipient-site vascular support, a later operation divides the pedicle and completes inset and contouring. This sequence describes exposed bridging-pedicle reconstruction. Selected tunneled, transposed, and deepithelialized interpolation variants can instead be completed in one operation, as described in the [original single-stage interpolation report](https://pubmed.ncbi.nlm.nih.gov/25158878/).
Apply it
For nasal coverage using a staged paramedian forehead flap with an exposed bridge, plan donor-site management, protection of the pedicle, and subsequent division and final inset. Explain the temporary appearance and confirm that the patient can return for completion. Division depends on adequate tissue perfusion and the particular reconstruction; the initial transfer does not establish that the flap can immediately survive without its pedicle.
Common pitfall: Premature pedicle division can compromise flap viability. Conversely, the term interpolation does not automatically imply later pedicle division: selected single-stage designs retain their vascular connection without an exposed bridge requiring subsequent removal. A tunneled pedicle also requires sufficient space to avoid compression or kinking of its blood supply.
ABD MDS Subspecialty Certification Examination Study Guide · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1 · Eyelid Reconstruction - EyeWiki
18.How does a free graft establish vascular support?
A free skin graft initially obtains nourishment from the recipient bed through imbibition. Inosculation and subsequent neovascularization establish vascular support. This sequence requires close, stable contact across the graft's undersurface. Hematoma, seroma, or shearing can interrupt the interface before vascular integration becomes secure. Edge sutures alone cannot ensure survival when the central graft is separated from the bed.
Apply it
A newly placed graft develops a central collection beneath otherwise secured edges. Assess the collection and loss of graft-bed contact promptly because central separation threatens nourishment and vascular integration.
Common pitfall: A graft may look neatly attached around its perimeter while losing contact centrally. Evaluate the entire interface and the recipient bed rather than relying only on edge appearance.
19.How does graft thickness alter reconstructive tradeoffs?
A split-thickness graft includes epidermis and part of the dermis; a full-thickness graft includes the entire dermis. The Iowa reference describes better survival but greater contraction with split-thickness grafts, while full-thickness grafts have greater nutritional demands and less contraction. Selection balances recipient-bed support, donor-site management, and the functional consequences of later contraction. Thickness alone does not determine the best repair.
Apply it
A defect lies near a structure where contraction could impair function. Weigh the lower contraction of a full-thickness graft against its greater recipient-bed requirements and the available donor site.
Common pitfall: Reliable initial take does not guarantee the best long-term functional result. Conversely, a favorable contraction profile cannot overcome an unsuitable recipient bed.
Nail surgery, scar revision, and tissue expansionnot stated
20.How do nail plate removal and diagnostic matrix biopsy differ?
Removing the nail plate provides access to underlying structures; it does not itself sample a germinal-matrix lesion. Diagnostic matrix biopsy obtains tissue for histopathology while seeking to preserve remaining nail-producing structures. The RACGP article illustrates plate removal, reflection of the proximal fold, direct visualization and excision of a matrix lesion, and fine absorbable repair. Matrix injury can cause permanent nail dystrophy.
Apply it
A patient needs diagnosis of a proximal pigmented lesion. Explain that plate removal permits access, while targeted tissue sampling supplies the diagnostic specimen. Plan the biopsy around the lesion's location.
Common pitfall: Access and diagnosis are different procedural objectives. Removing pigmented plate material can leave the causative matrix lesion unsampled, while poorly planned matrix injury can produce lasting deformity.
RACGP - Pigmented lesions of the nail bed – Clinical assessment · ABD MDS Subspecialty Certification Examination Study Guide
21.Why can longitudinal melanonychia arise from a proximal matrix lesion?
A proximal germinal-matrix lesion can generate pigment that becomes incorporated into the growing nail plate. The visible distal streak may therefore record pigment production at a more proximal source. Distal sampling can miss that source. Persistent or changing melanonychia requires localization and assessment for malignant features. Blind proximal punching may miss the lesion while injuring the matrix or creating scarring between tissue planes.
Apply it
A widening band extends from beneath the proximal fold to the free edge, but the distal bed appears normal after plate removal. Consider a proximal matrix origin and plan directly visualized sampling of the relevant lesion.
Common pitfall: The most accessible pigmented material is not necessarily the diagnostic target. Poor localization can yield inadequate tissue and permanent nail dystrophy.
RACGP - Pigmented lesions of the nail bed – Clinical assessment
22.Which growth pattern distinguishes keloid from hypertrophic scar?
A keloid extends beyond the original injury boundary, whereas a hypertrophic scar remains within it. Boundary behavior is more discriminating than height, redness, itching, or tenderness alone. Compare the lesion with the original wound footprint before classifying a raised scar. Recognition matters because a keloid's tendency to recur changes the discussion of excision, adjunctive treatment, and expectations for durable control.
Apply it
A firm lesion following an ear piercing expands well beyond the original puncture. Its growth outside the injury boundary favors keloid and warrants a recurrence-conscious treatment discussion.
Common pitfall: A thick or symptomatic scar is not automatically a keloid. Symptoms overlap, while extension beyond the original injury supplies a more useful distinction.
AAD: Keloid scars—Overview · AAD: Keloid scars—Diagnosis and treatment
23.Why must keloid excision include a recurrence-prevention plan?
Excision removes existing keloid tissue but creates another wound in a person predisposed to excessive scarring. Surgery alone frequently results in recurrence. The AAD describes combined approaches using treatments such as corticosteroid injections, pressure, or silicone according to the clinical setting. Silicone sheets belong on healed skin rather than an open area or scab. Treatment selection and treatment timing are separate decisions.
Apply it
Before excising a symptomatic keloid, discuss the recurrence risk and an appropriate adjunctive plan. If silicone sheets are selected, begin them after the wound surface has healed and the scab is gone.
Common pitfall: Complete removal does not eliminate the biological tendency to form keloids. Beginning scar therapy prematurely over an open wound confuses scar management with initial wound care.
24.What sequence and complications define tissue expansion?
An expander is placed in a pocket beneath selected skin. Once the incision heals, progressive filling stretches the overlying tissue. A later operation removes the expander and repositions the expanded skin. This provides nearby tissue with similar color, texture, and hair-bearing characteristics but requires repeated visits and staged surgery. Infection can interrupt expansion and may require removal, clearance of infection, and later reinsertion.
Apply it
A scalp expander develops infection shortly after placement. Reassess the device and reconstruction before further filling. If removal is necessary, revise the schedule around infection clearance and subsequent reconstruction.
Common pitfall: Meeting the original completion date does not justify continued filling through a device complication. Incision healing precedes expansion, and infection can require restarting the sequence.
Tissue Expansion Procedure Steps | American Society of Plastic Surgeons · Tissue Expansion Risks and Safety | American Society of Plastic Surgeons
Pre-, peri-, and postoperative carenot stated
25.How should patient factors alter perioperative planning?
Risk depends on the interaction between the procedure and the patient's healing capacity, comorbidities, medications, and ability to perform care. The ABD outline identifies diabetes, tobacco use, immunosuppression, tissue oxygenation, and medications affecting healing. Connect each material factor with a decision about reconstructive complexity, monitoring, wound-care support, or treatment setting. A diagnosis list becomes useful only when its implications are applied.
Apply it
An immunosuppressed patient has a large lower-leg defect and cannot independently manage dressings. Incorporate healing concerns and practical care capacity into reconstruction and follow-up planning.
Common pitfall: Defect dimensions alone do not establish a suitable repair. A technically available reconstruction may require a care burden or monitoring plan that the patient cannot safely manage.
ABD MDS Subspecialty Certification Examination Study Guide · ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
26.How should antithrombotic decisions balance competing harms?
Compare the bleeding consequences of the specific operation with the thrombotic consequences of interrupting medication. Relevant factors include the drug's indication, combinations of agents, patient history, and whether bleeding could threaten a repair or critical structure. The BSDS guidance supports individualized assessment. If alteration is contemplated, incorporate the prescribing context and relevant clinicians rather than applying a blanket rule.
Apply it
A patient anticoagulated after a recent thromboembolic event needs surgery with substantial bleeding consequences. Review urgency, procedural alternatives, and interruption-related thrombosis risk with the prescribing team.
Common pitfall: Stopping therapy solely because it increases bleeding ignores its protective purpose. Assuming all skin operations have equivalent bleeding consequences also overlooks anatomy and reconstructive complexity.
BSDS Guidance on Antithrombotics and Skin Surgery 2023, Version 2023.6
27.How should uncomplicated biopsy-site bleeding initially be managed?
For uncomplicated biopsy-site bleeding, apply firm, uninterrupted pressure with sterile gauze for 20 minutes. Repeatedly lifting the gauze interrupts compression and can disturb clot formation. AAD advises contacting the dermatologist if bleeding continues afterward. Brisk bleeding, rapidly expanding swelling, faintness, or systemic compromise requires immediate assessment rather than waiting through a routine home-pressure trial.
Apply it
A patient with slow oozing has been checking the site every minute. Explain continuous pressure for the full interval and contact with the treating clinician if the bleeding persists.
Common pitfall: Repeated checks can make an apparent pressure trial ineffective. The routine instruction for minor oozing must not delay escalation when bleeding is substantial or an expanding collection is developing.
28.Which postoperative changes raise concern for infection?
Increasing pain, spreading redness, warmth, swelling, purulent drainage, or fever warrant assessment for infection. Interpret these findings through their progression and timing. Mild early inflammation differs from a wound that worsens after initial improvement. The AAD wound-care guidance emphasizes recognizing warning signs and contacting the treating clinician. A photograph can assist triage but cannot establish that concerning progression is harmless.
Apply it
A previously improving wound develops increasing pain, expanding redness, and purulent drainage. Arrange clinical assessment rather than simply repeating the original routine dressing instructions.
Common pitfall: Redness alone is not synonymous with infection. Conversely, dismissing progressive pain and spreading inflammation as expected healing can delay recognition of a genuine postoperative complication.
29.Why are topical antibiotics unnecessary for routine clean wounds?
Routine topical antibiotics do not provide sufficient benefit to justify their use on every clean surgical wound. AAD's Choosing Wisely recommendation identifies allergic reactions and antimicrobial resistance as concerns. Appropriate cleansing, petrolatum, and a protective dressing support uncomplicated wound care. This recommendation concerns routine prophylaxis; a wound with suspected infection requires a separate assessment rather than automatic application of either routine-care rule.
Apply it
A patient requests antibiotic ointment for an uncomplicated incision. Explain petrolatum-based care, dressing technique, and warning signs, reserving antimicrobial treatment for a defined indication.
Common pitfall: An antibacterial label does not establish superior wound care. Contact dermatitis from an ointment can create new symptoms and resemble infection in an otherwise clean wound.
AAD Choosing Wisely recommendations · AAD: Skin biopsy—Dermatologist-recommended wound care
30.When should symptoms after local anesthesia suggest systemic toxicity?
Local anesthetic systemic toxicity can affect the central nervous and cardiovascular systems. A seizure, altered consciousness, significant arrhythmia, or cardiovascular instability temporally associated with administration should prompt immediate consideration of this emergency. Stop further anesthetic delivery and activate emergency assistance. ASRA provides a dedicated treatment framework because several resuscitation choices differ from ordinary cardiovascular arrest habits.
Apply it
A patient develops a seizure followed by cardiovascular instability during injection. Stop the injection, summon help, support oxygenation and circulation, and use the temporal relationship to recognize possible systemic toxicity.
Common pitfall: Attributing every procedural collapse to anxiety or a simple faint can delay treatment. Neurologic and cardiovascular abnormalities following anesthetic administration demand urgent reassessment.
ASRA Local Anesthetic Systemic Toxicity Checklist, 2020 v1.1
31.Which resuscitation choices are specific to local anesthetic toxicity?
ASRA's posted 2020 checklist, version 1.1, calls for airway support, prefers benzodiazepines for seizures, and advises early consideration of 20% lipid emulsion. If epinephrine is needed, smaller doses than usual are preferred. Vasopressin, beta-blockers, calcium-channel blockers, and additional local anesthetics should be avoided during LAST resuscitation. Lipid treatment complements oxygenation and circulatory support rather than replacing them.
Apply it
A proposed LAST treatment bundle includes a benzodiazepine, early lipid emulsion, and vasopressin. Retain the appropriate seizure and lipid measures but remove vasopressin and follow the checklist's cardiovascular approach.
Common pitfall: Recognition alone is insufficient when routine arrest drug choices are applied unchanged. Ready access to the checklist and rescue supplies supports correct emergency action.
ASRA Local Anesthetic Systemic Toxicity Checklist, 2020 v1.1 · ASRA: Checklist for Treatment of Local Anesthetic Systemic Toxicity
Cutaneous oncology agentsnot stated
32.How does vismodegib target basal cell carcinoma biology?
Vismodegib binds to and inhibits Smoothened, a transmembrane protein in Hedgehog signaling. Its pathway-directed mechanism differs from immune checkpoint blockade and light-activated local treatment. Identifying the target connects basal cell carcinoma biology with a treatment used in selected advanced disease. The molecular mechanism does not by itself establish suitability for a particular lesion; the clinical indication and safety requirements remain essential.
Apply it
A patient asks whether vismodegib acts like a PD-1 inhibitor. Explain Smoothened-directed Hedgehog inhibition and then address why systemic treatment is being considered for that patient's disease.
Common pitfall: A shared oncology role does not imply a shared mechanism or indication. Confusing Smoothened inhibition with immune checkpoint blockade obscures both treatment selection and counseling.
33.Why does response to topical therapy not prove deep clearance?
Topical treatment has limitations related to lesion depth and the absence of complete surgical margin assessment. NCI's discussion of topical fluorouracil warns that nonvisible dermal involvement can persist despite apparent surface response. Treatment selection therefore requires an established diagnosis and attention to subtype and risk. Flattening, reduced scale, or visible inflammation demonstrates treatment effect but does not independently establish eradication of deeper tumor.
Apply it
A thick lesion appears smoother after topical treatment, but the original biopsy demonstrated dermal involvement. Reassess using the established diagnosis rather than declaring clearance from the surface appearance.
Common pitfall: A dramatic inflammatory reaction is not a histologic clearance test. Apparent disappearance of superficial disease cannot compensate for using a treatment unsuitable for deeper involvement.
34.How does photodynamic therapy produce local cell injury?
Photodynamic therapy combines a photosensitizing agent, light of an appropriate wavelength, and tissue oxygen. Activation generates reactive oxygen species that produce local cellular injury. Its usefulness depends on appropriate lesion selection and delivery of these components. It does not provide mapped histologic margin assessment. The mechanism explains both its local effect and the importance of distinguishing suitable superficial disease from deeply invasive tumors.
Apply it
A patient asks whether ordinary illumination alone reproduces the treatment. Explain the linked roles of photosensitizer, appropriate light, and oxygen, then review why the diagnosed lesion is suitable.
Common pitfall: PDT is not simply heating the skin. Omitting the photosensitizing component or disregarding lesion depth changes the treatment and its expected effectiveness.
35.Which patients fit the 2025 adjuvant cemiplimab approval?
On October 8, 2025, FDA approved cemiplimab-rwlc for adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. This adjuvant setting differs from treatment of existing unresectable or metastatic disease. C-POST excluded solid organ transplant recipients and several other populations, limiting direct generalizability. Trial exclusion alone is not an automatic contraindication stated by the approval notice.
Apply it
An adult with high-risk cSCC has completed surgery and postoperative radiation. Discuss the adjuvant indication while separately assessing comorbidities, potential harms, and populations not directly represented in the trial.
Common pitfall: The approval does not establish routine treatment after every excised cSCC. Preserve the high-recurrence-risk and completed-local-treatment qualifiers when applying it.
FDA: Adjuvant cemiplimab-rwlc approval for cutaneous squamous cell carcinoma
36.Why do checkpoint inhibitors require assessment for immune toxicity?
PD-1 inhibitors reduce inhibitory signaling that restrains immune responses against cancer. Immune activation can also injure normal tissues, and the FDA cemiplimab notice highlights immune-mediated adverse reactions. New symptoms during treatment require consideration of toxicity alongside infection, progression, and unrelated disease. Counseling should explain that systemic immune effects can produce clinically important problems beyond the skin.
Apply it
A patient receiving cemiplimab develops persistent diarrhea and a widespread rash. Promptly involve the oncology team to assess possible immune-mediated toxicity rather than assuming the symptoms are unrelated.
Common pitfall: Describing treatment as simple immune support understates its risks. The antitumor mechanism and normal-organ injury arise from related immune effects, so new symptoms deserve timely attention.
NCI Skin Cancer Treatment PDQ—Health Professional Version · FDA: Adjuvant cemiplimab-rwlc approval for cutaneous squamous cell carcinoma
Radiation therapynot stated
37.What distinguishes definitive radiation from surgical margin assessment?
Definitive radiation can provide local treatment when surgery would be extensive or unsuitable, but it produces no excised specimen for complete histologic margin examination. Selection therefore weighs expected tumor control, tissue effects, functional consequences, and alternatives. An absence of surgery does not eliminate follow-up needs. Clinical response after radiation and histologic clearance of an excised surgical boundary are different forms of assessment.
Apply it
A patient comparing surgery with radiation asks whether radiation provides a pathology report showing clear margins. Explain that radiation treats tissue in place and discuss how response and later suspicious changes are evaluated.
Common pitfall: Avoiding an incision does not establish a risk-free treatment or a negative microscopic margin. Match counseling to the evidence each treatment can provide.
NCI Skin Cancer Treatment PDQ—Health Professional Version · ABD MDS Subspecialty Certification Examination Study Guide
38.Why do inherited cancer syndromes alter radiation selection?
Radiation can contribute to later malignancy, making inherited susceptibility relevant to treatment selection. NCI advises avoiding radiation in conditions predisposing to radiation-induced cancers, including basal cell nevus syndrome and xeroderma pigmentosum. This patient-specific limitation can outweigh an otherwise attractive local treatment option. Radiation's activity against a sporadic tumor does not establish its suitability for a person with inherited susceptibility.
Apply it
A young adult with basal cell nevus syndrome requests radiation for several BCCs to avoid surgery. Explain how the syndrome changes the risk-benefit balance and discuss suitable lesion-specific alternatives.
Common pitfall: Local convenience does not remove long-term susceptibility. Applying a treatment recommendation from sporadic disease without recognizing the inherited syndrome can expose the patient to additional harm.
39.How does adjuvant radiation address different Merkel cell risk compartments?
Definitive radiation serves as the principal local modality; adjuvant radiation supplements another treatment to address recurrence risk. NCI describes primary-site and regional radiation considerations in Merkel cell carcinoma. Risk at the original skin site and risk in a nodal basin are separate treatment questions. Clear primary margins therefore do not independently determine whether regional treatment is appropriate when adverse nodal findings are present.
Apply it
After resection of Merkel cell carcinoma, multiple regional nodes show disease with extranodal extension. Explain why regional adjuvant radiation addresses risks beyond the original skin lesion.
Common pitfall: A clear primary-site margin does not settle treatment of known nodal disease. Identify the intended radiation target and the specific risk supporting treatment of that compartment.
NCI Merkel Cell Carcinoma Treatment PDQ—Health Professional Version
Keratinocyte carcinomas and other nonmelanoma skin cancersnot stated
40.Why can recurrent facial carcinoma favor margin-controlled treatment?
Recurrence and poorly defined borders increase concern that the visible lesion underestimates microscopic extent. On the face, unnecessary widening may also sacrifice tissue important to function and reconstruction. Mohs combines mapped margin examination with directed additional removal, supporting treatment of selected recurrent or anatomically sensitive keratinocyte carcinomas. Assess oncologic uncertainty and tissue-conservation needs together rather than relying on location alone.
Apply it
A BCC recurs within a nasal scar and has indistinct borders. Explain how mapped assessment and directed stages address uncertain extension while preserving uninvolved nasal tissue.
Common pitfall: A small visible recurrence can have substantial subclinical extension. Surface diameter alone overlooks the implications of prior treatment, scar tissue, and poorly defined boundaries.
AAD: What is Mohs surgery? · ACMS: The Mohs Step-by-Step Process
41.What separates carcinoma in situ from invasive carcinoma?
Carcinoma in situ remains confined to its epithelial compartment; invasive carcinoma extends into underlying tissue. Invasion changes the relevance of depth, anatomic involvement, staging, and potential spread. NCI's AJCC head-and-neck cutaneous carcinoma framework designates in situ disease as Tis. A superficial biopsy establishes what was sampled but may not exclude a deeper component when clinical findings suggest tissue beyond the specimen is involved.
Apply it
A superficial biopsy shows SCC in situ, but the lesion has a firm deeper component absent from the sample. Obtain adequate assessment before choosing a treatment limited to superficial disease.
Common pitfall: The pathology label does not characterize unsampled tissue. Clinical-pathologic discordance should prompt clarification rather than automatic acceptance of a superficial treatment plan.
42.How does size determine early head-and-neck cutaneous carcinoma categories?
In the AJCC eighth-edition head-and-neck cutaneous carcinoma framework reproduced by NCI, T1 is no more than 2 cm and T2 is greater than 2 cm but no more than 4 cm, provided no higher-category feature applies. Eyelid carcinoma uses separate criteria. Identify the applicable anatomic staging system and assess invasion features before assigning a category from diameter.
Apply it
A 2.8-cm cheek cSCC has no qualifying deep invasion, perineural involvement, or bone involvement. Its size supports T2 within the specified framework after higher-category features are excluded.
Common pitfall: These thresholds cannot be applied indiscriminately to every skin site. Diameter also cannot override an independently qualifying feature that establishes a higher T category.
43.Which invasion features can establish T3 despite small diameter?
For applicable head-and-neck cutaneous carcinomas, AJCC eighth-edition T3 includes diameter greater than 4 cm, qualifying perineural invasion, deep invasion, or minor bone erosion. Deep invasion means beyond subcutaneous fat or more than 6 mm. Qualifying perineural invasion includes involvement of a nerve deeper than the dermis or at least 0.1 mm in caliber; NCI also describes qualifying clinical named-nerve involvement.
Apply it
A 1.7-cm temple cSCC involves a 0.12-mm nerve. In the absence of a higher-category feature, that qualifying perineural involvement supports T3 despite the small diameter.
Common pitfall: Size is only one route to a category. Ignoring depth, nerve caliber, or nerve location can substantially underestimate the primary tumor's classification.
44.How should immunosuppression change skin cancer assessment?
Immunosuppression changes the context of skin cancer risk and management. The ABD outline requires understanding risks associated with immunosuppressive agents and modifying care for immunosuppressed patients. Integrate treatment history, tumor burden, individual tumor findings, and surveillance needs. Medication decisions also require recognition of the condition being protected by immunosuppression, particularly a transplanted organ, so prevention and cancer treatment must be coordinated.
Apply it
A transplant recipient develops several keratinocyte carcinomas within months. Review their risk features and surveillance needs, and coordinate any proposed immunosuppression changes with the transplant team.
Common pitfall: Recognizing increased cancer risk does not justify unilateral withdrawal of transplant medication. Cancer control and graft protection require a shared plan based on both risks.
ABD MDS Subspecialty Certification Examination Study Guide · NCI Skin Cancer Treatment PDQ—Health Professional Version
45.Why do clinically negative nodes not exclude Merkel cell spread?
Merkel cell carcinoma can involve regional nodes before disease becomes clinically detectable. A normal nodal examination therefore establishes neither absence of microscopic metastasis nor pathologic node negativity. NCI recommends sentinel lymph node evaluation for patients without clinically detectable metastatic disease because occult regional involvement changes staging and management. Regional staging evaluates a separate disease compartment from the primary skin tumor.
Apply it
A patient with biopsy-proven Merkel cell carcinoma has no palpable nodes. Include sentinel-node evaluation in staging discussions rather than describing the patient as pathologically node negative.
Common pitfall: Clear primary margins and a normal nodal examination can both coexist with occult nodal metastasis. Local removal does not answer the regional staging question.
NCI Merkel Cell Carcinoma Treatment PDQ—Health Professional Version
46.What should surveillance after cutaneous SCC address?
Follow-up addresses recurrence of the treated cancer and development of additional primary skin cancers. AAD guideline highlights recommend at least annual checks, with frequency adjusted to individual risk. Examination should extend beyond the surgical scar. Risk-based surveillance, self-examination education, and sun protection connect successful treatment of one lesion with the patient's ongoing susceptibility to subsequent malignancy.
Apply it
After complete excision of cSCC, explain why dermatology follow-up continues after the incision heals. Tailor visit frequency to the patient's tumor history, risk factors, and current findings.
Common pitfall: A healed scar demonstrates wound recovery rather than freedom from future cancer. Restricting follow-up to the treated site can miss new lesions elsewhere on the skin.
AAD Cutaneous squamous cell carcinoma clinical guideline highlights
Melanoma and melanoma in situnot stated
47.Which nail findings favor melanoma over benign pigmentation or hemorrhage?
Concerning findings include a broad band greater than 3 mm, irregular colors, nonparallel lines, blurred borders, proximal widening, and pigmentation of adjacent nail-fold skin. Dystrophy or ulceration adds concern. Benign melanocytic bands more often have narrow width, homogeneous color, distinct borders, and parallel lines. Hemorrhage commonly shows homogeneous reddish-brown pigment migrating distally with nail growth. These patterns guide assessment but are not individually definitive.
Apply it
Distally migrating pigment with clear proximal growth supports hemorrhage. A widening irregular black band with proximal-fold pigmentation warrants prompt specialist diagnostic assessment.
Common pitfall: A remembered injury does not exclude melanoma. Neither a single width threshold nor absence of nail-fold pigmentation can independently establish benignity.
RACGP - Pigmented lesions of the nail bed – Clinical assessment
48.How should an incomplete melanoma depth measurement be interpreted?
Melanoma T classification uses thickness and ulceration. When invasive tumor reaches the specimen's deep boundary, the measured thickness may be a minimum because the deepest invasive extent was not captured. Distinguish a precise measurement from a complete assessment. Additional appropriate pathologic evaluation may provide information needed to establish the final category and inform regional staging discussions.
Apply it
A biopsy measures melanoma at 0.7 mm but contains invasive tumor at its deep edge. Explain that the lesion may be thicker and avoid a definitive low-risk classification from this incomplete sample.
Common pitfall: Numerical precision does not remove sampling uncertainty. Treating a transected depth measurement as the final Breslow thickness can incorrectly settle both classification and subsequent staging decisions.
NCI Melanoma Treatment PDQ—Health Professional Version · Importance of Vertical Pathology of Debulking Specimens During Mohs Micrographic Surgery for Lentigo Maligna and Melanoma in Situ
49.How do thickness and ulceration distinguish T1a from T1b melanoma?
Under AJCC eighth-edition criteria summarized by NCI, T1a is less than 0.8 mm without ulceration. T1b includes lesions less than 0.8 mm with ulceration and lesions 0.8–1.0 mm with or without ulceration. A nonulcerated 0.9-mm melanoma is therefore T1b. Primary T classification must remain distinct from complete stage grouping, which also incorporates regional and distant disease.
Apply it
Two melanomas both measure 0.7 mm. The nonulcerated lesion is T1a; the ulcerated lesion is T1b. Their equal thickness does not establish an identical category.
Common pitfall: Absence of ulceration does not make a 0.8–1.0-mm melanoma T1a. Conversely, ulceration changes the category of an otherwise thinner T1 lesion.
50.When should sentinel-node biopsy enter a thin-melanoma discussion?
NCI describes consideration of lymphatic mapping and sentinel lymph node biopsy for clinically node-negative melanoma at least 0.8 mm thick and for ulcerated thinner lesions. The procedure seeks occult regional disease and supplies prognostic information that can affect management. Consideration is an individualized discussion incorporating tumor findings, patient circumstances, procedural tradeoffs, and the consequences of the result.
Apply it
A healthy patient has a completely assessed nonulcerated 0.9-mm melanoma and no palpable nodes. Explain T1b classification and discuss sentinel-node biopsy's staging purpose, benefits, and limitations.
Common pitfall: Waiting until thickness exceeds 1 mm overlooks relevant thin-melanoma discussions. Describing biopsy as mandatory for every eligible discussion also overstates an individualized decision.
51.Why does microscopic nodal disease change melanoma stage?
Thickness describes the primary tumor but does not capture all disease extent. Regional nodal metastasis changes the N category and places melanoma within regional-stage groupings, even when the primary is thin. A positive sentinel node therefore supplies information that a normal nodal examination could not establish. Combine primary findings, regional involvement, and distant disease assessment only after identifying each component separately.
Apply it
A patient with a thin melanoma has a positive sentinel node and no distant metastasis. Explain that the nodal finding changes regional staging despite the small Breslow thickness.
Common pitfall: Calling disease early solely because the primary is thin obscures known regional spread. Primary T category and complete stage describe different dimensions of the cancer.
Coding and documentationnot stated
52.What makes Medicare Mohs coding an integrated service?
U.S. Medicare Mohs coding requires the same physician to perform surgical removal and histologic examination. NCCI treats the required components as integrated Mohs work, preventing duplicate reporting of routine excision and margin-pathology services for that work. Mapped tissue removal alone does not establish eligibility if another physician supplies the required histologic interpretation. Coding follows the service actually performed rather than the operative label.
Apply it
A surgeon removes tissue in mapped layers, but a different physician performs all slide interpretation. Evaluate appropriate excision and pathology reporting rather than assuming the procedure qualifies as integrated Mohs.
Common pitfall: A Mohs-style technique does not independently satisfy the same-physician requirement. Documentation must demonstrate the required surgical and interpretive roles.
CMS Medicare NCCI Policy Manual 2026, Chapter III · CMS Billing and Coding: Mohs Micrographic Surgery, A56514
53.How are Mohs tissue blocks distinguished from slides?
CMS defines a Mohs tissue block as an individual tissue piece embedded in mounting medium for sectioning. Multiple sections or slides from that embedded piece do not create additional blocks. Documentation should follow tissue pieces through mapping and embedding and distinguish those pieces from subsequent preparation. A stage, block, and slide describe different units and cannot be substituted for one another.
Apply it
Four individually embedded pieces each produce three slides. Record four blocks and twelve slides; additional sections from those same embedded pieces do not increase the block count.
Common pitfall: Counting glass slides as blocks can overstate reporting units. Recuts reflect further preparation of existing tissue and do not automatically create new embedded tissue pieces.
54.How do separate reconstruction and modifier 25 address different services?
The 2026 Medicare NCCI manual permits separate reporting of supported repairs, grafts, and flaps with Mohs. Modifier 25 concerns a significant, separately identifiable E&M service on the same day as a minor procedure, beyond its inherent evaluation and decision. A new patient or different diagnosis alone does not establish eligibility. Modifier 59 does not replace modifier 25 on an E&M service.
Apply it
Document qualifying reconstruction under its procedure rules. Separately assess whether substantial evaluation of a new dermatitis exceeds work inherent in the day's minor procedure and supports an E&M service with modifier 25.
Common pitfall: A modifier cannot create unperformed work. Separate reconstruction and separate E&M reporting require different supporting facts and should not be justified interchangeably.
55.When can a diagnostic biopsy be reported with same-day Mohs?
NCCI recognizes medically necessary diagnostic biopsy and qualifying frozen-section pathology used to establish a suspected lesion's nature before definitive Mohs. Routine tumor sampling and margin processing remain integrated work. A conditional plan for Mohs if malignancy is confirmed does not alone defeat reportability. Review prior pathology, the actual diagnostic need, documentation, and applicable modifier rules before deciding whether separate reporting is supported.
Apply it
No adequate diagnosis exists, and a medically necessary biopsy confirms malignancy before conditionally planned Mohs proceeds. Document that diagnostic purpose and assess the relevant reporting requirements.
Common pitfall: Timing alone does not distinguish an independent diagnostic service from bundled work. Neither an earlier sample nor an appended modifier makes routine Mohs processing separately reportable.
CMS Medicare NCCI Policy Manual 2026, Chapter III · CMS Billing and Coding: Mohs Micrographic Surgery, A56514
56.How does the specimen unit govern initial immunohistochemistry reporting?
Under the 2026 NCCI discussion, dividing one Mohs tumor specimen into several blocks does not create several specimen-level initial immunohistochemistry units. The initial single-antibody unit follows the specimen even when that antibody is applied to multiple blocks. Additional distinct antibodies follow their applicable rules. Keep the clinical specimen, embedded blocks, prepared slides, and antibodies conceptually separate when documenting ancillary studies.
Apply it
One specimen becomes three blocks, all stained with the same initial antibody. Recognize one specimen-level initial-antibody unit rather than treating each stained block as another initial specimen service.
Common pitfall: Accurate description of laboratory work does not justify using the wrong reporting unit. Processing subdivisions do not multiply the number of original specimens.
Regulatory compliancenot stated
57.How should used sharps be discarded under OSHA requirements?
OSHA requires contaminated disposable sharps to enter appropriate containers immediately or as soon as feasible after use. Containers must be closable, puncture resistant, leakproof on the sides and bottom, and correctly labeled or color-coded. Appropriate placement reduces the handling and transport needed for disposal. Safe practice depends on both suitable equipment and its practical availability where contaminated sharps are used.
Apply it
The only sharps container is across a busy hallway. Provide an appropriate container near the area of use so disposal does not require carrying an unprotected contaminated needle through shared traffic.
Common pitfall: An ordinary rigid waste bin does not automatically satisfy sharps-container requirements. Construction, identification, placement, and timely use each contribute to exposure prevention.
58.When does OSHA permit contaminated-needle recapping?
OSHA generally prohibits bending, recapping, or removing contaminated needles. An exception requires demonstrating that no alternative is feasible or that the action is required by a specific medical or dental procedure. When an exception applies, a mechanical device or one-handed technique must be used. First determine whether recapping is justified; only then determine the permissible technique for that justified action.
Apply it
A worker routinely recaps with both hands before walking to a container. Replace this routine with prompt disposal. Any procedure-specific exception requires the appropriate justification and permitted method.
Common pitfall: One-handed technique does not itself justify recapping. It addresses how a permitted exception is performed and does not convert convenience into a valid exception.
59.How should a laboratory select the appropriate CLIA certificate?
CMS requires certificate selection to match the highest testing complexity performed. A Certificate of Waiver does not authorize all nonwaived services. Directors of nonwaived laboratories must meet applicable education, training, and experience requirements. Applicants use Form CMS-116 and supporting documentation through the relevant state process, with separate processes in specified states. State requirements may add obligations beyond federal certification.
Apply it
An office with a Certificate of Waiver plans high-complexity testing. Confirm categorization, obtain the appropriate certification and qualified direction, and satisfy applicable state requirements before starting that service.
Common pitfall: The simplest test performed does not determine the certificate needed. Existing authorization for waived testing cannot be assumed to cover a newly added higher-complexity service.
60.How do engineering controls complement sharps-handling rules?
OSHA's bloodborne pathogens standard calls for engineering and work-practice controls to eliminate or minimize occupational exposure. A compliant sharps container is an engineering control; prompt disposal without unnecessary manipulation is a work practice. These measures work together. Equipment availability does not ensure safe use, and careful behavior cannot compensate for unsuitable disposal equipment or placement that makes safe disposal impractical.
Apply it
After a near miss involving a contaminated needle left on a tray, assess both container accessibility and the disposal workflow. Correct the physical arrangement and the delayed handling practice that allowed the exposure opportunity.
Common pitfall: Telling staff to be more careful leaves a preventable hazard unresolved when equipment or workflow contributes. Assess the system surrounding the sharp as well as individual technique.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Trace each positive microscopic finding through specimen, map sector, and patient anatomy before directing another stage.
- Establish margin adequacy before assigning negativity, and distinguish processing limitations from diagnostic uncertainty.
- Compare reconstruction through vascular supply, tissue movement, contraction, free-margin position, and feasibility of staged care.
- Localize nail-unit lesions, distinguish diagnostic access from tissue sampling, and plan scar or expansion treatment around healing and complications.
- Separate local clearance, primary tumor classification, and regional staging in cSCC, Merkel cell carcinoma, and melanoma.
- Apply treatment-setting qualifiers, individualized perioperative assessment, correct coding units, and applicable laboratory and occupational requirements.
A practical preparation plan
1. Map the complete outline
Use the official ABD outline as the full scope reference. Add study of BWH cSCC staging, chemoprevention, broader dermoscopy, familial melanoma management, additional immunostains, radiation adverse effects, HIPAA, and patient safety standards. Include the outline's rare tumors: sebaceous carcinoma, microcystic adnexal carcinoma, eccrine carcinoma, dermatofibrosarcoma protuberans, Kaposi sarcoma, extramammary Paget disease, angiosarcoma, atypical fibroxanthoma, undifferentiated pleomorphic sarcoma, and surgically relevant lymphomas.
2. Rehearse specimen-to-decision reasoning
Draw maps for peripheral, deep, and complex three-dimensional involvement. State whether each margin is adequately represented, where residual disease lies, and what the next specimen must demonstrate. Explain which technical correction addresses each preparation defect.
3. Compare repairs for the same defect
Compare natural healing, direct closure, flap, and graft for one facial defect. Explain force direction, vascular dependence, contraction, donor consequences, and the feasibility of staged care. Rehearse how infection changes an expansion plan.
4. Apply staging thresholds
Name the applicable staging system before using its thresholds. Practise head-and-neck cSCC size and invasion criteria, melanoma thickness-plus-ulceration categories, and the purpose of sentinel-node evaluation. Study BWH staging separately.
5. Explain every answer choice
Complete the twenty questions before reading their explanations. Identify the decisive finding and explain why each competing answer fails. Classify errors as missing knowledge, incorrect threshold, overlooked qualifier, or faulty application.
6. Use active recall and supervised practice
Review flashcards at spaced intervals and explain mechanisms aloud. Add supervised slide review and procedural instruction for visual and technical competencies. Extend coding study to the outline's other procedures and modifiers, including 51, 76, 78, and 79.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABD MDS Exam Study Guide page
- ABD MDS Subspecialty Certification Examination Study Guide
- ABD: MDS Practice Pathway Ends in 2025
- ACMS: The Mohs Step-by-Step Process
- ACMS Mohs Surgery Process infographic
- ACGME Micrographic Surgery and Dermatologic Oncology Milestones, Version 2.1
- Importance of Vertical Pathology of Debulking Specimens During Mohs Micrographic Surgery for Lentigo Maligna and Melanoma in Situ
- University of Iowa: Split Thickness Skin Graft
- ACMS: Reconstruction
- AAD: Keloid scars—Overview
- AAD: Keloid scars—Diagnosis and treatment
- ASRA: Checklist for Treatment of Local Anesthetic Systemic Toxicity
- ASRA Local Anesthetic Systemic Toxicity Checklist, 2020 v1.1
- AAD: Skin biopsy—Dermatologist-recommended wound care
- AAD Choosing Wisely recommendations
- BSDS Guidance on Antithrombotics and Skin Surgery 2023, Version 2023.6
- DailyMed: ERIVEDGE prescribing information
- FDA: Adjuvant cemiplimab-rwlc approval for cutaneous squamous cell carcinoma
- NCI Skin Cancer Treatment PDQ—Health Professional Version
- NCI Merkel Cell Carcinoma Treatment PDQ—Health Professional Version
- AAD: What is Mohs surgery?
- AAD Cutaneous squamous cell carcinoma clinical guideline highlights
- NCI Melanoma Treatment PDQ—Health Professional Version
- CMS Medicare NCCI Policy Manual 2026, Chapter III
- CMS Billing and Coding: Mohs Micrographic Surgery, A56514
- OSHA 29 CFR 1910.1030—Bloodborne pathogens
- What does the MDS subspecialty certification exam consist of?
- RACGP - Pigmented lesions of the nail bed – Clinical assessment
- Tissue Expansion Procedure Steps | American Society of Plastic Surgeons
- Tissue Expansion Risks and Safety | American Society of Plastic Surgeons
- Apply for a CLIA Certificate | CMS
- Eyelid Reconstruction - EyeWiki
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.